Header Logo

Connection

Frederick Raal to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Antibodies, Monoclonal.
Frederick Raal
Connection Strength
8,816
Antibodies, Monoclonal
  1. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,652
  2. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,586
  3. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
    View in: PubMed
    Score: 0,522
  4. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,512
  5. Effect of Alirocumab on Lipoprotein(a) Over =1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017 Jan 01; 119(1):40-46.
    View in: PubMed
    Score: 0,498
  6. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
    View in: PubMed
    Score: 0,483
  7. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016 05; 4(5):403-10.
    View in: PubMed
    Score: 0,477
  8. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,434
  9. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,434
  10. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
    View in: PubMed
    Score: 0,415
  11. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
    View in: PubMed
    Score: 0,412
  12. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,403
  13. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
    View in: PubMed
    Score: 0,380
  14. Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025 Jan 03; 27(1):22.
    View in: PubMed
    Score: 0,221
  15. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,214
  16. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
    View in: PubMed
    Score: 0,209
  17. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
    View in: PubMed
    Score: 0,208
  18. Evinacumab for Homozygous Familial Hypercholesterolemia. Reply. N Engl J Med. 2021 02 11; 384(6):e17.
    View in: PubMed
    Score: 0,169
  19. More aggressive lipid lowering in people with diabetes? Lancet Diabetes Endocrinol. 2019 08; 7(8):587-589.
    View in: PubMed
    Score: 0,151
  20. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
    View in: PubMed
    Score: 0,144
  21. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol. 2018 Sep - Oct; 12(5):1199-1207.
    View in: PubMed
    Score: 0,140
  22. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,136
  23. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1448-1457.
    View in: PubMed
    Score: 0,133
  24. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
    View in: PubMed
    Score: 0,125
  25. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
    View in: PubMed
    Score: 0,121
  26. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
    View in: PubMed
    Score: 0,117
  27. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99.
    View in: PubMed
    Score: 0,112
  28. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
    View in: PubMed
    Score: 0,112
  29. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
    View in: PubMed
    Score: 0,104
  30. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
    View in: PubMed
    Score: 0,102
  31. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
    View in: PubMed
    Score: 0,047
  32. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
    View in: PubMed
    Score: 0,046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.